Loading...
OTCM
NONOF
Market cap211bUSD
Dec 04, Last price  
47.00USD
1D
-2.02%
1Q
-14.26%
Jan 2017
31.65%
Name

Novo Nordisk A/S

Chart & Performance

D1W1MN
OTCM:NONOF chart
P/E
13.27
P/S
4.61
EPS
22.72
Div Yield, %
3.08%
Shrs. gr., 5y
-1.27%
Rev. gr., 5y
18.94%
Revenues
290.40b
+25.03%
33,713,685,04038,751,814,80041,888,774,00045,666,120,40051,078,000,00060,776,000,00066,346,000,00078,026,000,00083,572,000,00088,806,000,000107,927,000,000111,780,000,000111,696,000,000111,831,000,000122,021,000,000126,946,000,000140,800,000,000176,954,000,000232,261,000,000290,403,000,000
Net income
100.99b
+20.68%
5,856,397,4206,452,985,2008,535,266,0009,666,004,40010,768,000,00014,403,000,00017,097,000,00021,432,000,00025,184,000,00026,481,000,00034,860,000,00037,925,000,00038,130,000,00038,628,000,00038,951,000,00042,138,000,00047,757,000,00055,525,000,00083,683,000,000100,988,000,000
CFO
120.97b
+11.07%
8,699,492,4007,741,322,0009,997,870,00012,896,921,20015,378,000,00019,679,000,00021,374,000,00022,214,000,00025,942,000,00031,692,000,00038,287,000,00048,314,000,00041,168,000,00044,616,000,00046,782,000,00051,951,000,00055,000,000,00078,887,000,000108,908,000,000120,968,000,000
Dividend
Aug 15, 20240.517 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
IPO date
May 17, 1974
Employees
59,337
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT